# Leflunomide in Mild COVID-19 Patients

> **NCT04361214** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 11 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Leflunomide

## Key facts

- **NCT ID:** NCT04361214
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-05
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Terminated by PI
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361214, "Leflunomide in Mild COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04361214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*